Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID) (ACROVID)
Primary Purpose
COVID-19, Chilblains
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Biological Sample Collection
Sponsored by
About this trial
This is an interventional diagnostic trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- Patient over the age of majority or a minor over 12 years of age accompanied by his/her legal representative
- Benefiting from a Social Security scheme
- Informed consent signed by the patient (if major) or by his legal representative (if minor) after clear, fair and appropriate information about the study.
- Red and swollen lesions of the hands and/or feet evolving for more than 24 hours in the context of a COVID-19 epidemic.
- PCR SARS-CoV-2 PCR on nasopharyngeal swab with results available, prior to the inclusion visit.
- Absence of fever or respiratory signs suggestive of COVID-19 for at least 14 days
Exclusion Criteria:
- A person who does not benefit from a Social Security scheme or who does not benefit from it through a third party.
- Patient who is subject to a judicial safeguard measure
- Allergy to local anaesthetic products
- Fever or respiratory signs suggestive of COVID-19 within 14 days
Sites / Locations
- CHU de Poitiers
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Acrovid
Arm Description
Cohort
Outcomes
Primary Outcome Measures
Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.
Main Judgement Criterion Comparison between the proportion of patients with chilblains presenting a SARS-CoV-2 positive virological status and the estimated proportion of SARS-CoV-2 positive virological status in the general population.
The SARS-CoV-2 positive virological status of patients with chilblains will be defined by :
SARS-CoV-2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) on a positive nasopharyngeal swab pre-inclusion.
And/or RT-PCR SARS-CoV-2 on positive anal swab at D0
And/or RT-PCR SARS-CoV-2 on skin bubble fluid positive at D0.
And/or RT-PCR SARS-CoV-2 on skin biopsy positive at D0.
And/or SARS-CoV-2 serology positive at D0 and/or M1 and/or M2.
Secondary Outcome Measures
Study of the SARS-CoV-2 virological profile of patients presenting chilblains during a COVID-19 epidemic.
SARS-CoV-2 virological profile of patients with chilblains during a COVID-19 epidemic:
Proportion of patients with positive SARS-CoV-2 RT-PCR on pre-inclusion nasopharyngeal swab.
Proportion of patients with a positive RT-PCR SARS-CoV-2 on anal self-sampling at D0 +/- M1.
Proportion of patients with positive RT-PCR SARS-CoV-2 on skin bubble fluid collection at D0 +/- M1.
Proportion of patients with positive RT-PCR SARS-CoV-2 on skin biopsy at D0 and viral quantification.
Proportion of patients with positive SARS-CoV-2 serology at D0 and/or M1 and/or M2.
Proportion of SARS-CoV-2 positive serum neutralization in patients with SARS-CoV-2 positive serology at D0 and/or M1 and/or M2.
Proportion of patients with a positive viral culture at sites with positive PCR (nasopharyngeal or anal or bubble fluid or skin biopsy).
Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status (in case of over-representation of SARS-CoV-2 positive patients, the results will be given without comparison).
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
Proportions of each of the clinical signs detailed in the ACROVID data collection sheet in the Appendix.
Proportions of each of the biological characteristics detailed in the ACROVID data collection form in the Appendix.
Comparison of the capillaroscopic profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Proportions of each capillaroscopic abnormalities detailed in the ACROVID data collection sheet in the Appendix present during video capillaroscopy performed on all patient fingers (excluding thumbs) at D0 and M2.
Comparison of the TCPO2 profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Measurements of TCPO2 (expressed in mmHg) on the inter-metatarsal or metacarpal space of the two most affected toes or fingers.
Comparison of the toe or Finger Pressure Index profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Measurements of the toe or finger pressure index calculated as the ratio of the systolic toe or finger pressure measured on the most affected toe or finger (expressed in mmHg) and the average of the humeral systolic arterial pressure (SAP) measured per cuff on both arms (expressed in mmHg).
Comparison of histo-pathological profiles of chilblains according to their SARS-CoV-2 virological status of patients with the disease (in case of overrepresentation of SARS-CoV-2 positive patients, results will be given without comparison).
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Proportions of the histological characteristics of skin lesions detailed in the ACROVID data collection form in Appendix COVID-19
Comparison of the gene expression profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- Levels of messenger RiboNucleic Acid (mRNA) expression encoding cytokines, chemokines and interferon-induced genes involved in anti-viral response and inflammation in chilblains and Peripheral Blood Mononuclear Cell (PBMC) cultures.
Comparison of the immunostaining profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- Immunostaining profiles (qualitative) of cytokines, chemokines and interferon-induced proteins involved in anti-viral response and inflammation in chilblains biopsy sections.
Comparison of the ELISA assays profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- ELISA assays of cytokines and chemokines involved in anti-viral response and inflammation in plasma and PBMC supernatant from patients with chilblains.
Full Information
NCT ID
NCT04387955
First Posted
April 29, 2020
Last Updated
November 26, 2021
Sponsor
Poitiers University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04387955
Brief Title
Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)
Acronym
ACROVID
Official Title
Analysis of Chilblains Profile During COVID-19 Epidemic
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
April 30, 2020 (Actual)
Primary Completion Date
July 30, 2021 (Actual)
Study Completion Date
July 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Poitiers University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Cases of chilblains have been reported with an unusual frequency in France in the context of the COronaVirus Infectious Disease 2019 (COVID-19) epidemic. Some of these cases have been linked to a virological status in favour of a recent Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. Chilblains are acral inflammatory lesion typically reactive to cold (primary form). There are secondary forms acquired during autoimmune connectivitis such as lupus chilblain or hereditary forms related to type I Interferonopathy. An interferon type I signature has been described in these secondary forms of frostbite but also during the cytokine storm of severe forms of CoV-2 SARS infection. If cases of frostbite are indeed secondary to an SARS-CoV-2 infection, comparative analysis of their immunopathological profiles could provide a better understanding of the inflammatory mechanisms during COVID-19.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Chilblains
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective Cohort
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Acrovid
Arm Type
Other
Arm Description
Cohort
Intervention Type
Diagnostic Test
Intervention Name(s)
Biological Sample Collection
Intervention Description
Diagnostic test : biological sample collection at Day 0
Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)
Anal swabbing at Day 0
Blood test at Day 0
Blood test at Month 1
Blood test at Month 2
Primary Outcome Measure Information:
Title
Study of the link between SARS-CoV-2 infection and chilblains observed during COVID-19 epidemics.
Description
Main Judgement Criterion Comparison between the proportion of patients with chilblains presenting a SARS-CoV-2 positive virological status and the estimated proportion of SARS-CoV-2 positive virological status in the general population.
The SARS-CoV-2 positive virological status of patients with chilblains will be defined by :
SARS-CoV-2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) on a positive nasopharyngeal swab pre-inclusion.
And/or RT-PCR SARS-CoV-2 on positive anal swab at D0
And/or RT-PCR SARS-CoV-2 on skin bubble fluid positive at D0.
And/or RT-PCR SARS-CoV-2 on skin biopsy positive at D0.
And/or SARS-CoV-2 serology positive at D0 and/or M1 and/or M2.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Study of the SARS-CoV-2 virological profile of patients presenting chilblains during a COVID-19 epidemic.
Description
SARS-CoV-2 virological profile of patients with chilblains during a COVID-19 epidemic:
Proportion of patients with positive SARS-CoV-2 RT-PCR on pre-inclusion nasopharyngeal swab.
Proportion of patients with a positive RT-PCR SARS-CoV-2 on anal self-sampling at D0 +/- M1.
Proportion of patients with positive RT-PCR SARS-CoV-2 on skin bubble fluid collection at D0 +/- M1.
Proportion of patients with positive RT-PCR SARS-CoV-2 on skin biopsy at D0 and viral quantification.
Proportion of patients with positive SARS-CoV-2 serology at D0 and/or M1 and/or M2.
Proportion of SARS-CoV-2 positive serum neutralization in patients with SARS-CoV-2 positive serology at D0 and/or M1 and/or M2.
Proportion of patients with a positive viral culture at sites with positive PCR (nasopharyngeal or anal or bubble fluid or skin biopsy).
Time Frame
2 months
Title
Comparison of the clinical and biological profiles of patients presenting chilblains according to their SARS-CoV-2 virological status (in case of over-representation of SARS-CoV-2 positive patients, the results will be given without comparison).
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
Proportions of each of the clinical signs detailed in the ACROVID data collection sheet in the Appendix.
Proportions of each of the biological characteristics detailed in the ACROVID data collection form in the Appendix.
Time Frame
2 months
Title
Comparison of the capillaroscopic profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Proportions of each capillaroscopic abnormalities detailed in the ACROVID data collection sheet in the Appendix present during video capillaroscopy performed on all patient fingers (excluding thumbs) at D0 and M2.
Time Frame
2 months
Title
Comparison of the TCPO2 profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Measurements of TCPO2 (expressed in mmHg) on the inter-metatarsal or metacarpal space of the two most affected toes or fingers.
Time Frame
2 months
Title
Comparison of the toe or Finger Pressure Index profiles of patients with chilblains according to their SARS-CoV-2 virological status (in case of overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison).
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Measurements of the toe or finger pressure index calculated as the ratio of the systolic toe or finger pressure measured on the most affected toe or finger (expressed in mmHg) and the average of the humeral systolic arterial pressure (SAP) measured per cuff on both arms (expressed in mmHg).
Time Frame
2 months
Title
Comparison of histo-pathological profiles of chilblains according to their SARS-CoV-2 virological status of patients with the disease (in case of overrepresentation of SARS-CoV-2 positive patients, results will be given without comparison).
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status (if there is an overrepresentation of SARS-CoV-2 positive patients, the results will be given without comparison):
- Proportions of the histological characteristics of skin lesions detailed in the ACROVID data collection form in Appendix COVID-19
Time Frame
2 months
Title
Comparison of the gene expression profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- Levels of messenger RiboNucleic Acid (mRNA) expression encoding cytokines, chemokines and interferon-induced genes involved in anti-viral response and inflammation in chilblains and Peripheral Blood Mononuclear Cell (PBMC) cultures.
Time Frame
2 months
Title
Comparison of the immunostaining profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- Immunostaining profiles (qualitative) of cytokines, chemokines and interferon-induced proteins involved in anti-viral response and inflammation in chilblains biopsy sections.
Time Frame
2 months
Title
Comparison of the ELISA assays profiles of chilblains according to their SARS-CoV-2 virological status and in healthy subjects.
Description
Comparison between patients with chilblains with a positive SARS-CoV-2 status and patients with chilblains with a negative SARS-CoV-2 status and healthy subjects :
- ELISA assays of cytokines and chemokines involved in anti-viral response and inflammation in plasma and PBMC supernatant from patients with chilblains.
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patient over the age of majority or a minor over 12 years of age accompanied by his/her legal representative
Benefiting from a Social Security scheme
Informed consent signed by the patient (if major) or by his legal representative (if minor) after clear, fair and appropriate information about the study.
Red and swollen lesions of the hands and/or feet evolving for more than 24 hours in the context of a COVID-19 epidemic.
PCR SARS-CoV-2 PCR on nasopharyngeal swab with results available, prior to the inclusion visit.
Absence of fever or respiratory signs suggestive of COVID-19 for at least 14 days
Exclusion Criteria:
A person who does not benefit from a Social Security scheme or who does not benefit from it through a third party.
Patient who is subject to a judicial safeguard measure
Allergy to local anaesthetic products
Fever or respiratory signs suggestive of COVID-19 within 14 days
Facility Information:
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86000
Country
France
12. IPD Sharing Statement
Learn more about this trial
Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)
We'll reach out to this number within 24 hrs